clinical studylínchuáng yánjiū临床研究shows / indicatesxiǎnshì显示new drugxīn yào新药zorevunersen (epilepsy drug)Zuǒléifúnàsēn佐雷伏纳森to cause / makeshǐ使Dravet syndrome (severe epilepsy)Délāwéi Zōnghézhēng德拉韦综合征children with the diseasehuàn ér患儿epilepsy / seizuresdiānxián癫痫attacks / episodesfāzuò发作at mostzuì duō最多to reducejiǎnshǎo减少90 percentjiǔ chéng九成。
clinical study
línchuáng yánjiū
临床研究
shows / indicates
xiǎnshì
显示
new drug
xīn yào
新药
zorevunersen (epilepsy drug)
Zuǒléifúnàsēn
佐雷伏纳森
to cause / make
shǐ
使
Dravet syndrome (severe epilepsy)
Délāwéi Zōnghézhēng
德拉韦综合征
children with the disease
huàn ér
患儿
epilepsy / seizures
diānxián
癫痫
attacks / episodes
fāzuò
发作
at most
zuì duō
最多
to reduce
jiǎnshǎo
减少
90 percent
jiǔ chéng
九成
published
fābiǎo
发表
in
yú
于
New England Journal of Medicine
Xīn Yīnggélán Yīxué Zázhì
新英格兰医学杂志
(particle)
de
的
study
yánjiū
研究
confirmed / proved
zhèngshí
证实
new type / novel
xīnxíng
新型
drug
yàowù
药物
zorevunersen
Zuǒléifúnàsēn
佐雷伏纳森
can
kě
可
to cause / make
shǐ
使
Dravet syndrome
Délāwéi Zōnghézhēng
德拉韦综合征
children with the disease
huàn ér
患儿
per month
měi yuè
每月
epilepsy / seizures
diānxián
癫痫
attacks
fāzuò
发作
number of times
cìshù
次数
to reduce
jiǎnshǎo
减少
at most
zuì duō
最多
reaching / up to
dá
达
90 percent
jiǔ chéng
九成
the study
yánjiū
研究
also
hái
还
found
fāxiàn
发现
this / the mentioned
gāi
该
drug
yàowù
药物
during
zài
在
three-year
sān nián
三年
period / cycle
zhōuqī
周期
within
nèi
内
improved
gǎishàn
改善
(completion particle)
le
了
children with the disease
huàn ér
患儿
(particle)
de
的
cognitive function
rènzhī gōngnéng
认知功能
and
yǔ
与
quality of life
shēnghuó zhìliàng
生活质量
research team
yánjiū tuánduì
研究团队
already / has
yǐ
已
based on this
jù cǐ
据此
launched / initiated
qǐdòng
启动
larger-scale
guīmó gèng dà
规模更大
(particle)
de
的
phase 3
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
March 4, 2026 at 10:00 PM
one (measure word for research)
yī xiàng
一项
published
fābiǎo
发表
in
yú
于
New England Journal of Medicine
Xīn Yīnggélán Yīxué Zázhì
新英格兰医学杂志
(particle)
de
的
clinical study
línchuáng yánjiū
临床研究
shows / indicates
xiǎnshì
显示
new type / novel
xīnxíng
新型
drug
yàowù
药物
zorevunersen (epilepsy drug)
Zuǒléifúnàsēn
佐雷伏纳森
can
kě
可
to cause / make
shǐ
使
Dravet syndrome
Délāwéi Zōnghézhēng
德拉韦综合征
children with the disease
huàn ér
患儿
(particle)
de
的
epilepsy / seizures
diānxián
癫痫
attacks / episodes
fāzuò
发作
number of times
cìshù
次数
at most
zuì duō
最多
to reduce
jiǎnshǎo
减少
approximately
yuē
约
90 percent
jiǔ chéng
九成
Dravet syndrome
Délāwéi Zōnghézhēng
德拉韦综合征
is
shì
是
a type of
yī zhǒng
一种
caused by
yóu
由
SCN1A (sodium channel gene)
SCN1A
SCN1A
gene
jīyīn
基因
mutation
tūbiàn
突变
triggered by
yǐnfā
引发
(particle)
de
的
rare
hǎnjiàn
罕见
and
qiě
且
severe
yánzhòng
严重
(particle)
de
的
hereditary
yíchuánxìng
遗传性
epilepsy
diānxián
癫痫
currently
mùqián
目前
clinically
línchuáng shàng
临床上
still lacking
shàng wú
尚无
to cure completely
gēnzhì
根治
means / method
shǒuduàn
手段
this
cǐ xiàng
此项
study
yánjiū
研究
in total
gòng
共
included / enrolled
nà rù
纳入
81 people
bāshíyī míng
八十一名
age
niánlíng
年龄
between
zài
在
two
èr
二
to
zhì
至
18 years old
shíbā suì
十八岁
between
zhījiān
之间
(particle)
de
的
children with the disease
huàn ér
患儿
participants
cānyùzhě
参与者
before
zài
在
to receive
jiēshòu
接受
treatment
zhìliáo
治疗
before
qián
前
on average
píngjūn
平均
per month
měi yuè
每月
episodes
fāzuò
发作
seizures
diānxián
癫痫
approximately
yuē
约
17 times
shíqī cì
十七次
this / the mentioned
gāi
该
drug
yàowù
药物
(particle)
de
的
mechanism of action
zuòyòng jīzhì
作用机制
lies in
zàiyú
在于
through / by means of
tōngguò
通过
to increase / raise
tíshēng
提升
SCN1A gene
SCN1A
SCN1A
gene
jīyīn
基因
healthy
jiànkāng
健康
copy
fùběn
副本
(nominal marker)
suǒ
所
produced / generated
chǎnshēng
产生
(particle)
de
的
protein
dànbáizhì
蛋白质
level
shuǐpíng
水平
thereby / thus
cóng ér
从而
to restore
huīfù
恢复
nerve cells
shénjīng xìbāo
神经细胞
function
gōngnéng
功能
the study
yánjiū
研究
also
hái
还
found / discovered
fāxiàn
发现
this / the mentioned
gāi
该
drug
yàowù
药物
during
zài
在
three-year
sān nián
三年
trial period
shìyàn zhōuqī
试验周期
within
nèi
内
helped
bāngzhù
帮助
children with the disease
huàn ér
患儿
to improve
gǎishàn
改善
(completion particle)
le
了
cognitive function
rènzhī gōngnéng
认知功能
and
yǔ
与
quality of life
shēnghuó zhìliàng
生活质量
the majority
dà duōshù
大多数
adverse reactions
bùliáng fǎnyìng
不良反应
degree / extent
chéngdù
程度
relatively mild
jiào qīng
较轻
positive / encouraging
jījí
积极
(particle)
de
的
initial / preliminary
chūbù
初步
results
jiéguǒ
结果
prompted / led to
cù shǐ
促使
research team
yánjiū tuánduì
研究团队
to launch / initiate
qǐdòng
启动
(completion particle)
le
了
larger-scale
guīmó gèng dà
规模更大
(particle)
de
的
phase 3
sān qī
三期
clinical trial
línchuáng shìyàn
临床试验
expected
yùjì
预计
in
zài
在
the year 2026
2026 nián
2026年
the second quarter
dì èr jìdù
第二季度
to complete
wánchéng
完成
patient enrollment
huànzhě zhāomù
患者招募
analysts
fēnxī rénshì
分析人士
believe
rènwéi
认为
if
ruò
若
phase 3
sān qī
三期
data
shùjù
数据
to receive / obtain
dédào
得到
verification / confirmation
yànzhèng
验证
zorevunersen
Zuǒléifúnàsēn
佐雷伏纳森
is expected to / may
yǒu wàng
有望
to become
chéngwéi
成为
Dravet syndrome
Délāwéi Zōnghézhēng
德拉韦综合征
patients
huànzhě
患者
first
shǒu gè
首个
disease-modifying therapy
jíbìng xiūshì liáofǎ
疾病修饰疗法
to have / possess
jùyǒu
具有
milestone
lǐ chéng bēi
里程碑
significance
yìyì
意义
News in English
Lifestyle & CultureClinical Trial Shows New Drug Zorevunersen Cuts Seizures by Up to 91 Percent in Children With Dravet Syndrome
Published in the New England Journal of Medicine, the study confirmed zorevunersen can reduce monthly seizure frequency in children with Dravet syndrome by up to 91 percent. The research team found the drug also improved cognitive function and quality of life over a three-year period, and has already launched a larger Phase 3 trial.
More in Lifestyle & Culture
Arsenal (football club)Āsēnnà阿森纳to advance into / to push forward totǐnɡjìn挺进UEFA Champions LeagueŌuɡuàn欧冠final / championship matchjuésài决赛，to face / to compete againstduìzhèn对阵Paris Saint-Germain (PSG)Bālí Shènɡ Rì'ěrmàn巴黎圣日耳曼。
Arsenal (football club)
Āsēnnà
阿森纳
to advance into / to push forward to
tǐnɡjìn
挺进
UEFA Champions League
Ōuɡuàn
欧冠
final / championship match
juésài
决赛
to face / to compete against
duìzhèn
对阵
Paris Saint-Germain (PSG)
Bālí Shènɡ Rì'ěrmàn
巴黎圣日耳曼
Arsenal Reach Champions League Final to Face Paris Saint-Germain
NASAMěiguó Hángtiānjú美国航天局Nancy Grace Roman (astronomer)Nán Xī Gé Lěi Zī Luómàn南希·格蕾丝·罗曼space telescopetàikōng wàngyuǎnjìng太空望远镜to launchfāshè发射time / dateshíjiān时间moved up to / advanced totíqián zhì提前至September 20262026 nián 9 yuè2026年9月。
NASA
Měiguó Hángtiānjú
美国航天局
Nancy Grace Roman (astronomer)
Nán Xī Gé Lěi Zī Luómàn
南希·格蕾丝·罗曼
space telescope
tàikōng wàngyuǎnjìng
太空望远镜
to launch
fāshè
发射
time / date
shíjiān
时间
moved up to / advanced to
tíqián zhì
提前至
September 2026
2026 nián 9 yuè
2026年9月
NASA Roman Space Telescope Launch Moved Up to September 2026
Novak DjokovicDéyuē Kēwéiqí德约科维奇to advance / to qualifyjìnjí晋级French Open / Roland GarrosFǎwǎng法网third rounddì sān lún第三轮，willjiāng将to face / to take on (in competition)yíngzhàn迎战19-year-old19 suì19岁structural particlede的Joao FonsecaFēngsāikǎ丰塞卡。
Novak Djokovic
Déyuē Kēwéiqí
德约科维奇
to advance / to qualify
jìnjí
晋级
French Open / Roland Garros
Fǎwǎng
法网
third round
dì sān lún
第三轮
will
jiāng
将
to face / to take on (in competition)
yíngzhàn
迎战
19-year-old
19 suì
19岁
structural particle
de
的
Joao Fonseca
Fēngsāikǎ
丰塞卡
Djokovic Reaches Roland Garros Round Three to Face 19-Year-Old Fonseca
United KingdomYīngguó英国Maywǔyuè五月temperature / air temperatureqìwēn气温consecutive / in a rowliánxù连续two daysliǎng tiān两天to break (a record)pò破historical recordlìshǐ jìlù历史纪录。
United Kingdom
Yīngguó
英国
May
wǔyuè
五月
temperature / air temperature
qìwēn
气温
consecutive / in a row
liánxù
连续
two days
liǎng tiān
两天
to break (a record)
pò
破
historical record
lìshǐ jìlù
历史纪录
UK May Temperature Record Broken for Two Consecutive Days